New hope for tough ovarian cancer: first human trial of MEN2501 launches

NCT ID NCT07226427

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called MEN2501 in about 100 adults with ovarian cancer that has stopped responding to platinum chemotherapy. The main goals are to check safety and find the best dose. Researchers will also watch for signs that the drug shrinks tumors or slows the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Florida Cancer Specialists & Research Institute

    RECRUITING

    Sarasota, Florida, 34232, United States

  • Highlands Oncology Group

    RECRUITING

    Springdale, Arkansas, 72762, United States

  • Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06519, United States